{"success":true,"data":{"pressRelease":{"id":"169547","rtpr_id":"nBw7BzfRpa-20261014","ticker":"CERS","exchange":"NASDAQ","all_tickers":["CERS"],"title":"Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting","author":"Business Wire","published_at":"2026-10-14T20:30:00.679Z","article_body":"Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual\nMeeting\n\nCerus Corporation (Nasdaq: CERS) announced today that it will host an industry\nworkshop on the implementation and real-world experience with INTERCEPT\nPlatelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association\nfor the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking\nplace in Atlanta, Georgia from October 17 through October 19. The AABB Annual\nMeeting attracts healthcare professionals, scientists, and other experts from\naround the globe involved in transfusion medicine and biotherapies.\n\n“We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including\nan industry workshop focused on real-world experiences,” said Vivek\nJayaraman, Cerus’ president and chief executive officer. “The meeting\nprovides an important opportunity to share scientific data and engage with the\ntransfusion medicine community.”\n\nThe following is a select list of Cerus-related presentations and abstracts.\nAll presentation times are listed in Eastern Time (ET).\n\nCerus-Sponsored Industry Workshop at AABB\n\n\n * Sunday, October 18, 2026 – 1:00 p.m. - 2:00 p.m. ET. From Implementation to\nImpact: Real-World Experiences with INTERCEPT Platelets and IFC at Grady\nHealth System\n\n(Speakers: James Sikora, MD, MPH, medical director, transfusion services,\nGrady Health System; Yonique Keane-Dawes, technical specialist, MLS (ASCP),\nGrady Health System; Lerene Archer, technical specialist, MLS (AMT), Grady\nHealth System)\n\n\n\nA replay of the presentation will be available on Cerus’ products website\napproximately one to two weeks following the event at\nhttps://intercept-usa.com/.\n\nOral Presentations\n\n\n * Session: New Insights Into Infectious Disease Detection & Elimination In\nBlood Donations, Saturday, October 17, 2026, 9:30 a.m. – 10:30 a.m.\n\n\n\nBacterial Contamination of Platelets with Large Volume Delayed Sample (LVDS)\nCulture or Amotosalen/UVA Pathogen Reduction (PR) (Speaker: R. Benjamin)\n\n * Session: Advancing Safety & Quality in the Transfusion Service, Monday,\nOctober 19, 8:15 a.m. – 9:15 a.m.\n\n\n\nProspective Comparison of Pathogen-Reduced and Conventional Cryoprecipitate in\nLiver Transplantation (Speaker: S. Racine-Brzostek)\n\nPoster Presentations\n\nOn display Sunday, October 18, and Monday, October 19, 2026\n\n\n * Assessment of Process Performance and Product Quality When Applying a Novel\nIllumination Device for Pathogen Reduction of Platelets (Poster # P-BC-6)\n\n * In Vitro Evaluation of Trima Platelets in 100% Plasma Prepared with Pathogen\nReduction using an LED Illuminator (Poster # P-BC-55)\n\n * In Vitro Evaluation of Amicus Platelets in 65% PAS Prepared with Pathogen\nReduction with LED Illuminator (Poster # P-BC-54)\n\n * In Vivo Recovery and Survival Apheresis Platelets in 100% Plasma Treated with\nPathogen Reduction with LED Illuminator (Poster # P-BC-87)\n\n * INT200 LED Illuminator for Photochemical Inactivation of Bacteria in Platelet\nConcentrates (Poster # P-TS-53)\n\n * Development of the INT200 Illuminator for Photochemical Inactivation of\nViruses and Parasites in Platelet Concentrates (Poster # P-TS-26)\n\n * A Time/Motion Study to Assess Irradiated and Pathogen Reduced Platelet\nComponent Inventory Management and Workflow at a Large Academic Medical Center\nin the Mid-South U.S. (Poster # P-TS-5)\n\n * Two decades of amotosalen/UVA platelet and plasma hemovigilance in Europe\n(Poster # P-TS-97)\n\n * Operational Experience With Amotosalen/UVA Pathogen Reduction for On-Demand\nApheresis Platelets in Morelos, Mexico (Poster # P-IV-5)\n\nThe full program of Cerus-related abstracts can be found at the following\nlink: https://intercept-usa.com/2026-abstract-book/\n\nCerus representatives will be in the exhibition area at booth #915.\n\n*Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as\nINTERCEPT Fibrinogen Complex, or IFC.\n\nABOUT CERUS\n\nCerus Corporation is dedicated solely to safeguarding the world’s blood\nsupply and aims to become the preeminent global blood products company.\nHeadquartered in Concord, California, the company develops and supplies vital\ntechnologies and pathogen-protected blood components to blood centers,\nhospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood\nSystem for platelets and plasma is available globally and remains the only\npathogen reduction system with both CE mark and FDA approval for these two\nblood components. In the U.S., the INTERCEPT Blood System for\nCryoprecipitation is approved for the production of Pathogen Reduced\nCryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT\nFibrinogen Complex), a therapeutic product for the treatment and control of\nbleeding, including massive hemorrhage, associated with fibrinogen deficiency.\nThe INTERCEPT red blood cell system is under regulatory review in Europe, and\nin late-stage clinical development in the U.S. For more information about\nCerus, visit www.cerus.com and follow us on LinkedIn.\n\nCerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261014682249/en/\n(https://www.businesswire.com/news/home/20261014682249/en/)\n\nTim Lee – Head of Investor Relations\n\nCerus Corporation\n\nir@cerus.com\n\n925-288-6128\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7BzfRpa-20261014","title":"Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting","author":"Business Wire","ticker":"CERS","created":"2026-10-14T20:30:00.679Z","tickers":["CERS"],"exchange":"NASDAQ","article_body":"Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual\nMeeting\n\nCerus Corporation (Nasdaq: CERS) announced today that it will host an industry\nworkshop on the implementation and real-world experience with INTERCEPT\nPlatelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association\nfor the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking\nplace in Atlanta, Georgia from October 17 through October 19. The AABB Annual\nMeeting attracts healthcare professionals, scientists, and other experts from\naround the globe involved in transfusion medicine and biotherapies.\n\n“We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including\nan industry workshop focused on real-world experiences,” said Vivek\nJayaraman, Cerus’ president and chief executive officer. “The meeting\nprovides an important opportunity to share scientific data and engage with the\ntransfusion medicine community.”\n\nThe following is a select list of Cerus-related presentations and abstracts.\nAll presentation times are listed in Eastern Time (ET).\n\nCerus-Sponsored Industry Workshop at AABB\n\n\n * Sunday, October 18, 2026 – 1:00 p.m. - 2:00 p.m. ET. From Implementation to\nImpact: Real-World Experiences with INTERCEPT Platelets and IFC at Grady\nHealth System\n\n(Speakers: James Sikora, MD, MPH, medical director, transfusion services,\nGrady Health System; Yonique Keane-Dawes, technical specialist, MLS (ASCP),\nGrady Health System; Lerene Archer, technical specialist, MLS (AMT), Grady\nHealth System)\n\n\n\nA replay of the presentation will be available on Cerus’ products website\napproximately one to two weeks following the event at\nhttps://intercept-usa.com/.\n\nOral Presentations\n\n\n * Session: New Insights Into Infectious Disease Detection & Elimination In\nBlood Donations, Saturday, October 17, 2026, 9:30 a.m. – 10:30 a.m.\n\n\n\nBacterial Contamination of Platelets with Large Volume Delayed Sample (LVDS)\nCulture or Amotosalen/UVA Pathogen Reduction (PR) (Speaker: R. Benjamin)\n\n * Session: Advancing Safety & Quality in the Transfusion Service, Monday,\nOctober 19, 8:15 a.m. – 9:15 a.m.\n\n\n\nProspective Comparison of Pathogen-Reduced and Conventional Cryoprecipitate in\nLiver Transplantation (Speaker: S. Racine-Brzostek)\n\nPoster Presentations\n\nOn display Sunday, October 18, and Monday, October 19, 2026\n\n\n * Assessment of Process Performance and Product Quality When Applying a Novel\nIllumination Device for Pathogen Reduction of Platelets (Poster # P-BC-6)\n\n * In Vitro Evaluation of Trima Platelets in 100% Plasma Prepared with Pathogen\nReduction using an LED Illuminator (Poster # P-BC-55)\n\n * In Vitro Evaluation of Amicus Platelets in 65% PAS Prepared with Pathogen\nReduction with LED Illuminator (Poster # P-BC-54)\n\n * In Vivo Recovery and Survival Apheresis Platelets in 100% Plasma Treated with\nPathogen Reduction with LED Illuminator (Poster # P-BC-87)\n\n * INT200 LED Illuminator for Photochemical Inactivation of Bacteria in Platelet\nConcentrates (Poster # P-TS-53)\n\n * Development of the INT200 Illuminator for Photochemical Inactivation of\nViruses and Parasites in Platelet Concentrates (Poster # P-TS-26)\n\n * A Time/Motion Study to Assess Irradiated and Pathogen Reduced Platelet\nComponent Inventory Management and Workflow at a Large Academic Medical Center\nin the Mid-South U.S. (Poster # P-TS-5)\n\n * Two decades of amotosalen/UVA platelet and plasma hemovigilance in Europe\n(Poster # P-TS-97)\n\n * Operational Experience With Amotosalen/UVA Pathogen Reduction for On-Demand\nApheresis Platelets in Morelos, Mexico (Poster # P-IV-5)\n\nThe full program of Cerus-related abstracts can be found at the following\nlink: https://intercept-usa.com/2026-abstract-book/\n\nCerus representatives will be in the exhibition area at booth #915.\n\n*Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as\nINTERCEPT Fibrinogen Complex, or IFC.\n\nABOUT CERUS\n\nCerus Corporation is dedicated solely to safeguarding the world’s blood\nsupply and aims to become the preeminent global blood products company.\nHeadquartered in Concord, California, the company develops and supplies vital\ntechnologies and pathogen-protected blood components to blood centers,\nhospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood\nSystem for platelets and plasma is available globally and remains the only\npathogen reduction system with both CE mark and FDA approval for these two\nblood components. In the U.S., the INTERCEPT Blood System for\nCryoprecipitation is approved for the production of Pathogen Reduced\nCryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT\nFibrinogen Complex), a therapeutic product for the treatment and control of\nbleeding, including massive hemorrhage, associated with fibrinogen deficiency.\nThe INTERCEPT red blood cell system is under regulatory review in Europe, and\nin late-stage clinical development in the U.S. For more information about\nCerus, visit www.cerus.com and follow us on LinkedIn.\n\nCerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261014682249/en/\n(https://www.businesswire.com/news/home/20261014682249/en/)\n\nTim Lee – Head of Investor Relations\n\nCerus Corporation\n\nir@cerus.com\n\n925-288-6128\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-14T20:30:00.726663157Z","server_sent_at_ms":1792009800726},"received_at":"2026-10-14T20:30:00.777Z","source_url":"https://www.businesswire.com/news/home/20261014682249/en/"},"analysis":{"id":"157784","press_release_id":"169547","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Cerus will host an industry workshop on real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex at the AABB Annual Meeting in Atlanta, October 17-19.\n\nThe program includes oral presentations on pathogen reduction in blood donations and liver transplantation, plus nine poster presentations covering the INT200 LED Illuminator and two decades of European hemovigilance data.\n\nThe release is promotional scientific visibility with no new clinical, regulatory, or financial information; the workshop focuses on Grady Health System's implementation experience.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference presence for INTERCEPT franchise -- suppress unless new IFC data emerges."},"keyFigures":{},"quotedText":"We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including an industry workshop focused on real-world experiences","namedEntities":{"people":[{"name":"Vivek Jayaraman","role":"President and CEO"},{"name":"James Sikora, MD, MPH","role":"Medical director, transfusion services, Grady Health System"},{"name":"Yonique Keane-Dawes","role":"Technical specialist, Grady Health System"},{"name":"Lerene Archer","role":"Technical specialist, Grady Health System"},{"name":"Tim Lee","role":"Head of Investor Relations"}],"products":["INTERCEPT Platelets","INTERCEPT Fibrinogen Complex (IFC)","INTERCEPT Blood System","INT200 LED Illuminator"],"companies":[{"name":"Cerus Corporation","ticker":"CERS"},{"name":"Grady Health System","relationship":"customer"},{"name":"Association for the Advancement of Blood and Biotherapies (AABB)","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Conference-workshop and abstract announcement with no new data, financials, or regulatory milestones. Routine scientific-community visibility for INTERCEPT products."},"tickerRelevance":{"others":[],"primary":"CERS"},"globalImportance":10,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-visibility","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Cerus will host an industry workshop on real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex at the AABB Annual Meeting in Atlanta, October 17-19.\n\nThe program includes oral presentations on pathogen reduction in blood donations and liver transplantation, plus nine poster presentations covering the INT200 LED Illuminator and two decades of European hemovigilance data.\n\nThe release is promotional scientific visibility with no new clinical, regulatory, or financial information; the workshop focuses on Grady Health System's implementation experience.","key_figures":{},"named_entities":{"people":[{"name":"Vivek Jayaraman","role":"President and CEO"},{"name":"James Sikora, MD, MPH","role":"Medical director, transfusion services, Grady Health System"},{"name":"Yonique Keane-Dawes","role":"Technical specialist, Grady Health System"},{"name":"Lerene Archer","role":"Technical specialist, Grady Health System"},{"name":"Tim Lee","role":"Head of Investor Relations"}],"products":["INTERCEPT Platelets","INTERCEPT Fibrinogen Complex (IFC)","INTERCEPT Blood System","INT200 LED Illuminator"],"companies":[{"name":"Cerus Corporation","ticker":"CERS"},{"name":"Grady Health System","relationship":"customer"},{"name":"Association for the Advancement of Blood and Biotherapies (AABB)","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T20:30:09.389Z","global_importance":10,"audience_relevance":8,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-visibility","issuerAuthored":true}},"durationMs":4028,"modelName":"glm-5.3-flashx"}}